
Claims:

1. Use of (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure




, or a pharmaceutically acceptable salt thereof and venetoclax or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a hematological malignancy in a subject in need thereof, wherein an effective amount of the (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, or a pharmaceutically acceptable salt thereof and an effective amount of the venetoclax, or a pharmaceutically acceptable salt thereof is to be administered to the subject.

2. The use of claim 1, wherein the (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof is to be administered sequentially, separately or simultaneously with venetoclax or a pharmaceutically acceptable salt thereof.

3. The use of claim 1 or 2, wherein the hematological malignancy is selected from acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), chronic lymphocytic leukaemia (CLL), and chronic myelomonocytic leukemia (CMML).


4. A compound (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure



, or a pharmaceutically acceptable salt thereof for

use in the treatment of a hematological malignancy, wherein the treatment comprises separate, sequential or simultaneous administration of venetoclax or a pharmaceutically acceptable salt thereof.

5. A compound Venetoclax or a pharmaceutically acceptable salt thereof for use in the treatment of a hematological malignancy, wherein the treatment comprises separate, sequential or simultaneous administration of (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure



, or a pharmaceutically acceptable salt thereof.

6. The compound or the pharmaceutically acceptable salt thereof for use of claim 4 or 5, wherein the hematological malignancy is selected from acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), chronic lymphocytic leukaemia (CLL), and chronic myelomonocytic leukemia (CMML).

7. The use of any one of claims 1 to 3, wherein an effective amount of 5-azacitidine is to be further administered.

8. The compound or the pharmaceutically acceptable salt thereof for use of any one of claims 4 to 6, wherein an effective amount of 5-azacitidine is to be further administered.


9. The use of claim 3, wherein the hematological malignancy is a relapsed or refractory hematological malignancy.

10. The compound or the pharmaceutically acceptable salt thereof for use of claim 6, wherein the hematological malignancy is a relapsed or refractory hematological malignancy.

11. The use of claim 3, wherein the hematological malignancy is resistant to a monotherapy of a BCL-2 inhibitor.


12. The compound or the pharmaceutically acceptable salt thereof for use of claim 6, wherein the hematological malignancy is resistant to a monotherapy of a BCL-2 inhibitor.

13. A kit comprising:

a first pharmaceutical composition comprising (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure  , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and

a second pharmaceutical composition comprising venetoclax or a pharmaceutically acceptable salt thereof and instructions for use.

14. The kit of claim 13, which further comprises a third pharmaceutical composition comprising 5-azacitidine.

15. A pharmaceutical product comprising i) (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one, having the structure  , or a pharmaceutically acceptable salt thereof, and ii) venetoclax or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical product of claim 15, wherein (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or

a pharmaceutically acceptable salt thereof and venetoclax or a pharmaceutically acceptable salt thereof are present in a single dosage form.

17. The pharmaceutical product of claim 15, wherein (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and venetoclax or a pharmaceutically acceptable salt thereof are present in separate dosage forms.